Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2A | Q12879 | 3/20 | 0.54 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.54 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.42 |
| ▸ | GRM5 | P41594 | 2/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.40 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.38 |
| ▸ | VNN1 | O95497 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16615938 | 0.86 | GRIN2A (0.51) | GRIN2AGRIN1GRIN2BADORA2AADORA1 | |
| SCHEMBL16615837 | 0.83 | VNN1 (0.48) | GRIN2AGRIN1GRM5ALDH1A1GAA | |
| SCHEMBL16713071 | 0.82 | GRIN2A (0.47) | GRIN2AGRIN1GRIN2BADORA2AADORA1 | |
| SCHEMBL16615818 | 0.80 | GRIN2A (0.62) | GRIN2AGRIN1GRIN2BGRM5ALDH1A1 | |
| SCHEMBL16598065 | 0.77 | GRIN2A (0.51) | GRIN2AGRIN1GRIN2BPDE10AALDH1A1 | |
| SCHEMBL16598064 | 0.77 | GRIN2A (0.54) | GRIN2AGRIN1GRIN2BADORA2AADORA1 | |
| SCHEMBL16615880 | 0.76 | GRIN2A (0.59) | GRIN2AGRIN1GRIN2BPDE10AALDH1A1 | |
| SCHEMBL16615821 | 0.74 | GRIN2A (0.65) | GRIN2AGRIN1GRIN2BALDH1A1GAA | |
| SCHEMBL16615958 | 0.73 | GRIN2A (0.77) | GRIN2AGRIN1GRIN2BALDH1A1 | |
| SCHEMBL16598156 | 0.73 | GRIN2A (0.47) | GRIN2AGRIN1GRIN2BADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9963434-B2 | N-arylmethyl sulfonamide negative modulators of NR2A | LUC THERAPEUTICS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-9963434-B2 | N-arylmethyl sulfonamide negative modulators of NR2A | LUC THERAPEUTICS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-20160311782-A1 | N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A | NOVARTIS AG (CH) | 2016-10-27 | — | — | US | disclosed |
| US-20160311782-A1 | N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A | NOVARTIS AG (CH) | 2016-10-27 | — | — | US | disclosed |
| US-20150141433-A1 | N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A | MNEMOSYNE PHARMACEUTICALS, INC. | 2015-05-21 | — | — | US | disclosed |
| US-20150141433-A1 | N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A | MNEMOSYNE PHARMACEUTICALS, INC. | 2015-05-21 | — | — | US | disclosed |
| WO-2015048503-A2 | N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A | MNEMOSYNE PHARMACEUTICALS, INC. (US) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311782-A1 | N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A | GRIN2A, GRIN2B, NR2C2 | GRIN2A 1/4885GRIN1 5/4885GRIN2B 2/4885 |
| US-20150141433-A1 | N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A | GRIN2A, GRIN2B, NR2C2 | GRIN2A 1/4885GRIN1 5/4885GRIN2B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.